The Journal of Diabetology, published by Wolters Kluwer Medknow Publications, is a premier platform dedicated to advancing the understanding and management of diabetes and related metabolic disorders. Since its inception in 2010, this Open Access journal has provided researchers and healthcare professionals with a wealth of knowledge through rigorous peer-reviewed articles that cover clinical research, epidemiology, and innovative treatment strategies. With an E-ISSN of 2078-7685 and a commitment to disseminating high-quality scientific work, the journal plays a pivotal role in contributing to the global discourse on diabetes care and prevention. Its dedication to accessibility enhances its impact on both established scholars and emerging researchers seeking to make meaningful contributions in the field. By fostering a collaborative environment, the Journal of Diabetology aims to bridge the gap between research and practical implementation, ultimately improving outcomes for individuals affected by diabetes.

DIABETES, published by the American Diabetes Association, is a premier journal in the field of endocrinology, diabetes, and metabolism, renowned for its rigorous peer-reviewed research since its inception in 1952. With an impressive impact factor and classified in the Q1 category for both Endocrinology, Diabetes and Metabolism and Internal Medicine as of 2023, it holds a prestigious position within the scholarly community, ranked 17th out of 244 in its specialization. The journal's objective is to disseminate cutting-edge research and advance scientific understanding to ultimately improve diabetes patient care and management. While it does not offer open access options, the journal remains a vital resource for researchers, professionals, and students involved in diabetes-related studies. The ongoing dedication to excellence by the authors, reviewers, and editors ensures that DIABETES continues to be a pivotal platform for innovation and knowledge in the fight against diabetes.

Diabetology & Metabolic Syndrome is a premier open-access journal published by BMC, dedicated to advancing the field of endocrinology, diabetes, and metabolic syndrome. Since its inception in 2009, the journal has established itself as a leading platform for original research, reviews, and clinical studies, offering comprehensive insights into the complexities of metabolic diseases. With an impressive ranking in the 2023 category quartiles as Q1 in both Endocrinology, Diabetes and Metabolism, and Internal Medicine, it stands among the top-tier journals in its field. Researchers will appreciate its strong emphasis on disseminating critical findings that influence clinical practices and public health policies. Accessible to a global audience, Diabetology & Metabolic Syndrome's commitment to open access enables the distribution of high-quality research without barriers, fostering an inclusive environment for knowledge sharing. With a strategic focus on the intersection of diabetes management and metabolic disorders, this journal is essential for professionals seeking to stay abreast of the latest developments and contribute to a vital area of healthcare.

ACTA DIABETOLOGICA, published by SPRINGER-VERLAG ITALIA SRL, is a distinguished peer-reviewed journal dedicated to the rapidly evolving fields of endocrinology, diabetes, and metabolism. With an impressive convergence of research from 1991 to 2024, it is recognized for its significant contributions, boasting a Q1 ranking in Internal Medicine and Q2 rankings in Endocrinology categories as of 2023. Its Scopus rankings further highlight its impact, placing it in the 81st percentile in Internal Medicine. The journal serves as a vital platform for professionals and researchers, facilitating the dissemination of innovative findings and fostering a comprehensive understanding of metabolic disorders. Although the journal is not open access, it remains an essential resource, ensuring high visibility and accessibility of critical research to its scholarly audience.

Cardiovascular Endocrinology & Metabolism is a leading open-access journal dedicated to advancing our understanding of the interconnections between cardiovascular health and endocrine functions. Published by Lippincott Williams & Wilkins, this journal serves as a vital resource for researchers and clinicians alike, providing timely insights into the intricate relationships between metabolic disorders and cardiovascular diseases. With an impressive impact factor and categorized in Q2 for both Cardiology and Cardiovascular Medicine as well as Endocrinology, Diabetes, and Metabolism, it holds a significant position within its respective fields. The journal has been fully open access since its inception in 2012, ensuring that critical research is accessible to a global audience. By fostering innovation and collaboration, Cardiovascular Endocrinology & Metabolism aims to promote better health outcomes and stimulate novel research directions, making it an essential resource for professionals striving to bridge the gaps between these two critical domains.

Diabetologie is a dedicated academic journal published by Springer Heidelberg, focusing on the diverse fields of endocrinology, diabetes, and metabolism. With the ISSN 2731-7447 and E-ISSN 2731-7455, this journal serves as a significant platform for the dissemination of innovative research and evidence-based practices within the rapidly evolving landscape of diabetes care and management. Although currently not classified as Open Access, the journal provides robust subscription options that grant access to a wealth of peer-reviewed articles, making it an invaluable resource for researchers and practitioners alike. With an H-index that reflects its emerging influence and a Scopus ranking in the 10th percentile within its category, Diabetologie aims to elevate the scientific understanding of diabetes through rigorous scholarship. The journal captures the latest findings and clinical advancements from 2022 to 2024, placing a particular emphasis on novel therapeutic strategies and technological innovations. By fostering a collaborative environment dedicated to the improvement of diabetes outcomes, Diabetologie stands as a crucial contributor to the global dialogue on diabetes treatment and research.

Therapeutic Advances in Endocrinology and Metabolism is a premier open-access journal published by SAGE Publications Ltd that has established itself as a leading platform for research in the field of endocrinology, diabetes, and metabolism. With a commitment to disseminating high-quality research, the journal aims to advance our understanding of therapeutic interventions and innovations in the management of endocrine disorders. Since its inception in 2010, it has garnered a strong reputation, attaining a Q1 quartile ranking in 2023 in its category and boasting a respectable Scopus rank of #53 out of 244, positioning it within the 78th percentile. As an open-access journal since 2019, Therapeutic Advances in Endocrinology and Metabolism ensures that valuable research findings are accessible to a global audience, fostering collaboration and knowledge sharing among researchers, clinicians, and students alike. The journal's multifaceted objectives encompass the publication of original research, reviews, and clinical studies that contribute to the evolving dialogue surrounding endocrine health. By delivering timely and robust content, it serves as an indispensable resource for those striving to make significant contributions to this vital area of medical science.

DIABETES OBESITY & METABOLISM, published by Wiley, is a premier international journal dedicated to the fields of endocrinology, diabetes, and metabolic disorders. With an impressive impact factor and its status as a Q1 journal in multiple categories—including Endocrinology and Internal Medicine—this publication is highly regarded in the academic community. Since its inception in 1999, the journal has served as a crucial platform for the dissemination of cutting-edge research, reviews, and clinical studies, driving advancements in understanding and treatment of diabetes and obesity. Researchers and professionals alike benefit from its rigorous peer-review process and extensive reach, as it aims to bridge the gap between laboratory findings and clinical applications. Although not an Open Access journal, articles are accessible through institutional subscriptions, ensuring that vital knowledge reaches those committed to enhancing patient care and expanding the scientific body of work in these pivotal areas.

Journal of Endocrinology and Metabolism is a dynamic and essential publication in the field of endocrinology, diabetes, and metabolism, published by ELMER PRESS INC in Canada. With an ISSN of 1923-2861 and E-ISSN 1923-287X, this journal serves as a pivotal platform for sharing innovative research and advancements from 2018 through 2024. Although categorized in the fourth quartile (Q4) for 2023, its commitment to high-quality research is reflected in its ongoing efforts to foster scholarly dialogue and illuminate critical issues within its scope. Targeting primarily researchers, healthcare professionals, and students, the journal aims to disseminate crucial findings that advance our understanding of endocrine functions and metabolic processes. Given its Scopus ranking of #207 out of 244 within its category, the Journal of Endocrinology and Metabolism continues to contribute to the global discourse on these vital health topics.

The Journal of Diabetes, published by WILEY, is a premier Open Access platform since 2022, dedicated to advancing knowledge in the fields of endocrinology, diabetes, and metabolism. With an ISSN of 1753-0393 and an E-ISSN of 1753-0407, this journal provides a vital resource for researchers and practitioners looking to keep up with the latest findings and trends in diabetes management and treatment. As of 2023, it holds a commendable Q2 rating in its category and ranks #78 out of 244 in the Scopus classification, placing it in the 68th percentile, thus affirming its significance in the academic community. Covering a timeline from 2009 to 2024, the journal invites submissions that contribute to the understanding of diabetes pathophysiology, innovative therapies, and clinical practices, making it an essential read for anyone dedicated to improving patient outcomes in diabetes care.